The redesigned follitropin alfa pen injector: results of the patient and nurse human factors usability testing

被引:19
|
作者
Schertz, Joan C. [1 ]
Saunders, Helen [2 ]
Hecker, Clara [3 ]
Lang, Barbara [3 ]
Arriagada, Pablo [4 ]
机构
[1] EMD Serono Inc, Fertil Global Clin Dev Unit, Rockland, MA 02370 USA
[2] Merck Serono SA, Fertil & Endocrinol Global Clin Dev Unit, Geneva, Switzerland
[3] Point Blank Int Mkt Res & Consultancy GmbH, Berlin, Germany
[4] Merck Serono SA, Fertil Global Clin Dev Unit Global Med Affairs, Geneva, Switzerland
关键词
follitropin alpha; human factors; in vitro fertilization; infertility; injection device; pen injector; recombinant human follicle-stimulating hormone; usability testing; OVULATION INDUCTION; DEVICE; DRUGS; WOMEN;
D O I
10.1517/17425247.2011.608350
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: A redesigned pen injector for administration of follitropin alfa (follitropin alpha) has been developed for use in fertility treatment cycles. Pre-summative and summative usability testing was undertaken to assess the risk of dosing errors compared with the existing follitropin a pen. The study also assessed proper use of and dose selection with the redesigned pen. Methods: Infertile women who were trying to conceive and specialist nurses were recruited from four cities in Germany. Usability goals relating to proper use of the pen device were defined from a risk assessment and further categorized as critical and functional operational goals. Individual, non-interventional, standardized, usability tests were performed with patients and nurses by four experienced research professionals using questionnaires that also included ease-of-use ratings. A non-standardized qualitative analysis of nurse-patient training sessions was performed in the presence of a research professional; reasons for confidence, safety, possible misunderstandings and risks when handling the pen were noted. Results: The overall risk of dosing errors with the redesigned pen was not higher than with the existing pen. No unexpected operational risks and no major concerns regarding the risk of misuse or dosing errors were identified. Conclusions: The study provides useful practical information on the redesigned pen from both patient and nurse perspectives.
引用
收藏
页码:1111 / 1120
页数:10
相关论文
共 50 条
  • [1] Patient evaluation of the redesigned follitropin alfa pen injector
    Schertz, Joan
    Worton, Hilary
    EXPERT OPINION ON DRUG DELIVERY, 2017, 14 (04) : 473 - 481
  • [2] A redesigned follitropin alfa pen injector for infertility: results of a market research study
    Abbotts, Carole
    Salgado-Braga, Cristiana
    Audibert-Gros, Celine
    PATIENT PREFERENCE AND ADHERENCE, 2011, 5 : 315 - 331
  • [3] Usability engineering study in the European Union of a redesigned follitropin alfa pen injector for infertility treatment
    Jeannerot, Fabien
    Stuedeli, Thomas
    Gunther-LaVergne, Lisa
    Hirning, David
    Schertz, Joan
    EXPERT OPINION ON DRUG DELIVERY, 2016, 13 (09) : 1221 - 1229
  • [4] Dose accuracy of the redesigned follitropin alfa pen injector for infertility treatment
    Jeannerot, Fabien
    Cusin, Alexandra
    Schertz, Joan
    Expert Opinion on Drug Delivery, 2016, 13 (12) : 1661 - 1669
  • [5] PATIENT AND NURSE EVALUATION OF THE IMPROVED FOLLITROPIN ALFA PEN INJECTOR FOR INFERTILITY TREATMENT.
    Schertz, J.
    Feilding, B.
    Worton, H.
    FERTILITY AND STERILITY, 2016, 106 (03) : E117 - E118
  • [6] The redesigned follitropin α pen injector for infertility treatment
    Christen, Michel
    Schertz, Joan C.
    Arriagada, Pablo
    Keitel, Joachim
    Mueller, Heiko
    EXPERT OPINION ON DRUG DELIVERY, 2011, 8 (06) : 833 - 839
  • [7] Human factors engineering and design validation for the redesigned follitropin alfa pen injection device
    Mahony, Mary C.
    Patterson, Patricia
    Hayward, Brooke
    North, Robert
    Green, Dawne
    EXPERT OPINION ON DRUG DELIVERY, 2015, 12 (05) : 715 - 725
  • [8] The recombinant human chorionic gonadotropin prefilled pen: results of patient and nurse human factors usability testing
    Saunders, Helen
    Schertz, Joan C.
    Hecker, Clara
    Lang, Barbara
    Arriagada, Pablo
    EXPERT OPINION ON DRUG DELIVERY, 2012, 9 (08) : 893 - 900
  • [9] Managing infertility with the follitropin alfa prefilled pen injector - patient considerations
    Buehler, Klaus
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 995 - 1001
  • [10] Dose accuracy of the follitropin alfa pen injector 2.0, the follitropin alfa:lutropin alfa 2:1 combination pen injector 2.0 and the choriogonadotropin alfa pen injector 1.0 used for fertility treatment
    Cottell, Evelyn
    Michalet, Damien
    Lispi, Monica
    Araujo, Thiago Dantas
    Gleixner, Ralf
    Longobardi, Salvatore
    D'Hooghe, Thomas
    EXPERT OPINION ON DRUG DELIVERY, 2024, 21 (02) : 337 - 346